Document Detail

Beta-Blockers in the Management of Hypertension and/or Chronic Kidney Disease.
Jump to Full Text
MedLine Citation:
PMID:  24672712     Owner:  NLM     Status:  PubMed-not-MEDLINE    
This minireview provides current summaries of beta-blocker use in the management of hypertension and/or chronic kidney disease. Accumulated evidence suggests that atenolol is not sufficiently effective as a primary tool to treat hypertension. The less-than-adequate effect of beta-blockers in lowering the blood pressure and on vascular protection, and the unfavorable effects of these drugs, as compared to other antihypertensive agents, on the metabolic profile have been pointed out. On the other hand, in patients with chronic kidney disease, renin-angiotensin system blockers are the drugs of first choice for achieving the goal of renal protection. Recent studies have reported that vasodilatory beta-blockers have adequate antihypertensive efficacy and less harmful effects on the metabolic profile, and also exert beneficial effects on endothelial function and renal protection. However, there is still not sufficient evidence on the beneficial effects of the new beta-blockers.
Hirofumi Tomiyama; Akira Yamashina
Publication Detail:
Type:  Journal Article; Review     Date:  2014-01-30
Journal Detail:
Title:  International journal of hypertension     Volume:  2014     ISSN:  2090-0384     ISO Abbreviation:  Int J Hypertens     Publication Date:  2014  
Date Detail:
Created Date:  2014-03-27     Completed Date:  2014-06-24     Revised Date:  2014-06-24    
Medline Journal Info:
Nlm Unique ID:  101538881     Medline TA:  Int J Hypertens     Country:  United States    
Other Details:
Languages:  eng     Pagination:  919256     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Int J Hypertens
Journal ID (iso-abbrev): Int J Hypertens
Journal ID (publisher-id): IJHY
ISSN: 2090-0384
ISSN: 2090-0392
Publisher: Hindawi Publishing Corporation
Article Information
Download PDF
Copyright © 2014 H. Tomiyama and A. Yamashina.
Received Day: 26 Month: 11 Year: 2013
Accepted Day: 23 Month: 12 Year: 2013
Print publication date: Year: 2014
Electronic publication date: Day: 30 Month: 1 Year: 2014
Volume: 2014E-location ID: 919256
PubMed Id: 24672712
ID: 3941231
DOI: 10.1155/2014/919256

Beta-Blockers in the Management of Hypertension and/or Chronic Kidney Disease
Hirofumi TomiyamaI1*
Akira YamashinaI1
Second Department of Internal Medicine, Tokyo Medical University, 6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan
Correspondence: *Hirofumi Tomiyama:
[other] Academic Editor: Kazushi Tsuda

1. Preface

Several recent meta-analyses have questioned the usefulness of beta-blockers as the primary tools to treat hypertension [13]. This has led to hesitation in the proper use of beta-blockers in the management of hypertension and chronic kidney disease (CKD). This review describes the opinion base promoting the use of beta-blockers for the treatment of hypertension and CKD.

2. Hypertension
2.1. Why Are Beta-Blockers Less Effective in the Prevention of Cardiovascular Events Than Other Antihypertensive Agents

Prichard classified beta-blockers into three types according to their beta1-selectivity and vasodilatory potential [4]. An additional classification is lipophilic or hydrophilic beta-blockers [5, 6]. Atenolol is a beta1-selective agent, and it has been widely used as the control drug in large randomized prospective controlled trials of newer antihypertensive agents such as calcium channel blockers and renin-angiotensin (RA) system blockers. Table 1 summarizes the plausible reasons why beta-blockers are considered to be relatively ineffective for the prevention of cardiovascular events [79].

In the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) study, blood pressure values were lower in those allocated to the calcium channel blocker-based regimen as compared to those allocated to the beta-blocker-based regimen throughout the trial period [10]. Recently, Webb et al. reported a meta-analysis in which they described visit-to-visit blood pressure instability in patients receiving beta-blocker treatment [11], and also that this instability was associated with an increased risk of stroke [12]. Atenolol was used in the ASCOT-BPLA study, and not only the analysis conducted by Webb et al. [11] but also that conducted by Rothwell et al. [12] involved the use of atenolol. Some studies demonstrated that once-daily atenolol does not provide adequate blood pressure control during the night-time and early morning periods because of its pharmacokinetic profile and half-life [13, 14]. These drug profiles of atenolol may be the cause for its relatively weak blood pressure-lowering effect and the blood pressure instability. On the other hand, metoprolol or bisoprolol have been shown to be more effective in sustaining 24-hour and early morning BP reductions as compared with atenolol [15, 16].

In the arterial tree, the arteries branch and taper as they reach peripheral sites, associated with the increase of the arterial resistance. Reflected pulse wave (from the periphery to the heart) occurs at sites of abrupt increase of the arterial resistance, such as at sites of arterial branching. Interaction between the incident pulse wave (from the heart to the periphery) and reflected pulse wave (from the periphery to the central region) is observed in the arterial tree (Figure 1); therefore, the blood pressure values differ between central and peripheral sites of the arterial tree [17]. Central (aortic and carotid) blood pressure is pathophysiologically more relevant than the peripheral pressure in the pathogenesis of cardiovascular disease [18]. Augmentation index (AI), a marker of the interaction of incident pressure wave and reflected pressure wave, was significantly and inversely related to heart rate due to an alteration in the relative timing of the reflected pressure wave [19]. Beta-blockers reduce the heart rate and decrease AI, which reduces their efficacy in reducing the central blood pressure as compared to other antihypertensive agents [20]. In their meta-analysis, Fagard et al. reported that beta-blockers exert a relatively weak effect in causing regression of the left ventricular mass [21]. In Fagard et al.'s review, atenolol was used in about 70% of the study subjects prescribed beta-blockers, and no study involving the use of vasodilatory beta-blockers was included. Recently, the advantages of nebivolol, a vasodilatory beta-blocker, over conventional β-blockers in reducing the central blood pressure and inducing regression of the left ventricular mass have been reported [22]. Compared with atenolol, nebivolol exerts a more favorable effect on 24-hour blood pressure profile [23]. Furthermore, nebivolol and telmisartan, an angiotensin II receptor blocker, decreased the left ventricular mass to a similar degree [24].

Shahin et al. reported that angiotensin-converting enzyme inhibitors improve endothelial function and are superior antihypertensive agents as compared to calcium channel blockers and beta-blockers [25]. However, in all of the studies cited in their meta-analysis, atenolol had been used as the beta-blocker. In contrast to atenolol, carvedilol and nebivolol also improve the endothelial function [26, 27].

While the meta-analysis conducted by Messerli et al. reported the unfavorable effects of beta-blockers on the metabolic profiles, this analysis did not include studies in which vasodilatory beta-blockers had been used [28]. More recent studies have reported the relatively less harmful effects of vasodilatory beta-blockers on the metabolic profiles and also on weight gain [29, 30].

As described above, new generations of beta-blockers, such as the long-acting and/or vasodilatory beta-blockers may overcome the relatively weak effect of beta-blockers in preventing cardiovascular events.

2.2. Concerns about Recent Meta-Analyses

A Cochrane Collaboration analysis conducted by Wiysonge et al., which was a representative analysis to evaluate the usefulness of beta-blockers in the management of hypertension, suggested that first-line beta-blocker use was not as good as other classes of antihypertensive drugs to decrease the mortality or morbidity [1, 2]. In his review, 60–70% of the subjects were receiving atenolol. As mentioned above, there is some doubt about the suitability of atenolol as a first-line antihypertensive drug, because of its low lipophilic profile and relatively weak effect on cardiovascular protection [5].

The MAPHY study demonstrated the significantly lower risk for coronary events in patients on metoprolol, a lipophilic beta-blocker, as compared to those on diuretics [31]. The usefulness of lipophilic beta-blockers for the prevention of cardiovascular events is still under debate [5, 6]. The meta-analysis conducted by Wiysonge et al. (total number of analyzed subjects, 91561) reported the higher risk for cardiovascular events in patients on beta-blockers as compared to those on diuretics. However, the number of study subjects prescribed metoprolol included in their meta-analysis was 7663 (8.4%). On the other hand, the meta-analysis conducted by Turnbull et al. (total number of study subjects for the comparison of the outcomes of major cardiovascular events (angiotensin converting enzyme inhibitor or calcium antagonist versus beta-blocker) was 14583, which was calculated from Figure 4 in [32]) demonstrated no evidence of any difference in the effect between beta-blockers and other classes of antihypertensive agents in preventing major cardiovascular events [32]. This meta-analysis included two studies in which metoprolol alone was used in the beta-blocker arm and two other studies in which metoprolol was used as one of the beta-blockers in the beta-blocker arm. The number of study subjects prescribed metoprolol included in this meta-analysis was 10062 (13.5%). Thus, the meta-analysis conducted by Turnbull et al. might have included a lower number of subjects prescribed atenolol and higher number of study subjects prescribed metoprolol, as compared to the meta-analysis conducted by Wiysonge et al. [1]. Then, recently, Turnbull et al. suggested that lipophilic beta-blockers may be preferable to hydrophilic beta-blockers for reducing the mortality in patients with coronary artery disease [33], though lipophilic β-blockers are associated with an increased risk of depressive symptoms [34].

Lindholm et al. reported that the differential effects between nonatenolol beta-blockers and other antihypertensive drugs on the risk of major cardiovascular events could not be fully evaluated because of the small number of studies including subjects prescribed nonatenolol beta-blockers [3]. Anyhow, atenolol is one of the most widely used beta-blockers, and more than 50% of the data in previous meta-analyses were derived from subjects prescribed atenolol. A meta-analysis to examine the effects of lipophilic and/or vasodilatory beta-blockers on the risk of major cardiovascular events is proposed.

2.3. Heart Rate in Beta-Blockers

The meta-analysis conducted by Bangalore et al. demonstrated an inverse relationship between beta-blocker-induced heart rate lowering and the reduction in the risk of future cardiovascular events in patients with hypertension [35]. This heart rate lowering causes a pseudoantihypertensive effect; that is, the central aortic pressure becomes less than the brachial pressure [7, 17, 18]. This phenomenon is thought to be one of mechanisms underlying the lower cardiovascular-protective effects of beta-blockers. On the other hand, high heart rate is known as an independent risk factor for major cardiovascular events. The risk seems to increase as the heart rate begins to exceed 70 bpm [36]. The aforementioned meta-analysis conducted by Bangalore et al. demonstrated an inverse relationship between heart rate and cardiovascular events in subjects with heart rates under 70 bpm, and no study until the current date has examined the relationship between the heart rate and the risk for cardiovascular events in cases receiving beta-blocker treatment with heart rates over 70 bpm. Furthermore, atenolol was used in more than 80% of the study subjects of the meta-analysis conducted by Bangalore et al. [35]. Thus, no study has examined the association between the reduction in heart rate and the increased risk of cardiovascular events by the treatment with beta-blockers other than atenolol. Our previous prospective study identified high heart rate as an independent risk factor for vascular damage (increase in arterial stiffening) [37]. Therefore, it has not been concluded that beta-blocker-induced heart rate lowering increases the risk of cardiovascular events in cases with heart rate over 70 bpm. In the case of patients with hypertension and a high heart rate, we have sometimes experienced good efficacy of beta-blockers for the control of both the blood pressure and the heart rate (Figure 2).

3. CKD
3.1. Renal Protection and Beta-Blockers in CKD

In addition to the prevention of cardiovascular events, renal protection is crucial in the management of CKD. Recent guidelines recommended RA system blockers as the agents of first choice for the management of hypertension in patients with CKD, because of the significant renal-protective effects of this class of drugs [38, 39]. On the other hand, the sympathetic nervous system is activated in CKD [40, 41], which acts as a key player in the progression of renal dysfunction and may also contribute to the onset/progression of cardiovascular disease [40, 41]. However, reduction of the cardiac output and the consequent impairment of renal perfusion caused by beta-blockers are thought to be harmful in patients with CKD [42]. Actually, recent studies have demonstrated that only 20–30% of patients with CKD are prescribed beta-blockers [43, 44].

The Kidney Disease Outcomes Quality Initiative (K/DOQI) guideline recommend that beta-blockers be used as the third-line antihypertensive agents in patients with proteinuria [45]. However, as mentioned above, while meta-analyses have suggested the demerits of atenolol in the management of hypertension [13], controversial results of the renal-protective effects of atenolol as compared to those of other antihypertensive agents were reported in subjects with hypertension accompanying CKD [46, 47]. Concerning other beta-blockers, the African American Study of Kidney Disease and Hypertension Study (AASK Trials) demonstrated the absence of any significant differences in the clinical composite outcomes (renal function decline, onset of end-stage renal disease, and/or death) between patients treated with metoprolol and those treated with amlodipine [48]. Two multicenter studies reported the renal protective effects of carvedilol, a vasodilatatory beta-blocker [29, 49]. Thus, it has not yet been concluded whether beta-blockers (especially vasodilatory beta-blockers) may simply represent third-line of antihypertensive agents for the management of hypertension in patients with CKD. Further study is proposed to clarify whether calcium channel blockers (especially nondihydropyridines, which reduce proteinuria) [50] or vasodilatory beta-blockers may be more suitable for renal protection and controlling blood pressure in patients with CKD.

3.2. Prevention of Cardiovascular Events, including Sudden Death, and Beta-Blockers in CKD

Traditional risk factors such as hypertension, diabetes mellitus, and dyslipidemia, and nontraditional risk factors such as inflammation, oxidative stress, abnormal mineral metabolisms, hyperparathyroidism, homocysteinemia, and anemia are known to be associated with cardiovascular events in patients with CKD [51]. The reported rate of sudden cardiac death in patients with end-stage renal disease is 50-fold higher than that in the general population [52]. In addition to the prevalence of coronary artery disease and/or heart failure, left ventricular hypertrophy, electrolyte abnormalities such as hyperkalemia, and vascular calcification might also be associated with sudden cardiac death in patients with CKD [52].

Badve et al.'s meta-analysis demonstrated that beta-blockers reduce the risk of all-cause and cardiovascular mortality in patients with CKD and systolic heart failure [53]. Basically, in their review, studies involving the use of beta-blockers other than atenolol were included, and ACE inhibitors were concomitantly prescribed for most of the patients in these studies. However, their meta-analysis did not evaluate the effect of beta-blockers on sudden cardiac death. The hemodialysis (HEMO) study suggested a trend towards the benefit of beta-blockers for the prevention of sudden cardiac death in patients with CKD and coronary heart disease, but not in CKD patients without coronary artery disease (this study did not describe the details about the kind of beta-blockers used, e.g., atenolol) [54].

4. Summary
4.1. Hypertension

This review does not support the use of beta-blockers as the primary tool to treat hypertension. However, it does propose proper use of beta-blockers, especially in cases with high heart rate and/or resistant hypertension, considering their long-acting, vasodilatory, and/or lipophilic profiles.

4.2. CKD

Beta-blockers are recommended as second-line agents after RA system blockers for controlling hypertension in patients with CKD and systolic heart failure. As compared to other antihypertensive agents, except RA system blockers, it has been confirmed that there are no demerits to using beta-blockers for renal protection. In addition, vasodilatory beta-blockers may also have beneficial renal-protective effects. Even in patients with CKD, control of blood pressure is crucial for the prevention of cardiovascular events. While the combination of RA system blockers with diuretics is effective for reducing the blood pressure, in CKD often three or more different antihypertensive drugs are required to control blood pressure level. Then, there is no evidence that beta-blockers, especially vasodilatory beta blockers, are inferior to diuretics or calcium channel blockers as second- or third-line agents for renal protection and control of blood pressure in patients with CKD [55].

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

1. Wiysonge CS,Bradley H,Mayosi BM,et al. Beta-blockers for hypertensionCochrane Database of Systematic ReviewsYear: 20071CD0020032-s2.0-34248198272
2. Wiysonge CS,Bradley H,Mayosi BM,et al. Beta-blockers for hypertensionCochrane Database of Systematic ReviewsYear: 20128CD0020032-s2.0-34248198272
3. Lindholm LH,Carlberg B,Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysisThe LancetYear: 20053669496154515532-s2.0-27544463207
4. Prichard BNC. The second Lilly Prize Lecture, University of Newcastle, July 1977. β-Adrenergic receptor blockade in hypertension, past, present and futureBritish Journal of Clinical PharmacologyYear: 1978553793992-s2.0-001809046226370
5. Hjalmarson Å. Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?Basic Research in CardiologyYear: 200095supplement 1I41I452-s2.0-003453788411192352
6. Rinfret S,Abrahamowicz M,Tu J,et al. A population-based analysis of the class effect of β-blockers after myocardial infarctionAmerican Heart JournalYear: 200715322242302-s2.0-3384623340817239680
7. Carlberg B,Samuelsson O,Lindholm LH. Atenolol in hypertension: is it a wise choice?The LancetYear: 20043649446168416892-s2.0-13844314822
8. De Caterina AR,Leone AM. The role of beta-blockers as first-line therapy in hypertensionCurrent Atherosclerosis ReportsYear: 20111321471532-s2.0-7995590380421207202
9. Elliott WJ,Childers WK. Should β blockers no longer be considered first-line therapy for the treatment of essential hypertension without comorbidities?Current Cardiology ReportsYear: 20111365075162-s2.0-8125521030221898116
10. Dahlöf B,Sever PS,Poulter NR,et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialThe LancetYear: 200536694898959062-s2.0-24644443331
11. Webb AJ,Fischer U,Mehta Z,Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysisThe LancetYear: 201037597189069152-s2.0-77749282912
12. Rothwell PM,Howard SC,Dolan E,et al. Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of strokeThe Lancet NeurologyYear: 2010954694802-s2.0-77950629667
13. Neutel JM,Schnaper H,Cheung DG,Graettinger WF,Weber MA. Antihypertensive effects of β-blockers administered once daily: 24-hour measurementsAmerican Heart JournalYear: 199012011661712-s2.0-00252949642360502
14. Morgan TO,Anderson A. Different drug classes have variable effects on blood pressure depending on the time of dayAmerican Journal of HypertensionYear: 200316146502-s2.0-003723562712517682
15. Sarafidis P,Bogojevic Z,Basta E,Kirstner E,Bakris GL. Comparative efficacy of two different beta-blockers on 24-hour blood pressure controlThe Journal of Clinical HypertensionYear: 20081021121182-s2.0-4204910461618259123
16. Neutel JM,Smith DHG,Ram CVS,et al. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agentsThe American Journal of MedicineYear: 19939421811872-s2.0-00275022708430713
17. Tomiyama H,Yamashina A. Non-invasive vascular function tests: their pathophysiological background and clinical applicationCirculation JournalYear: 201074124332-s2.0-7514915704819920359
18. Vlachopoulos C,Aznaouridis K,O’Rourke MF,Safar ME,Baou K,Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysisEuropean Heart JournalYear: 20103115186518712-s2.0-7795481431820197424
19. Dhakam Z,McEniery CM,Yasmin Y,Cockcroft JR,Brown MJ,Wilkinson IB. Atenolol and eprosartan: dfferential effects on central blood pressure and aortic pulse wave velocityAmerican Journal of HypertensionYear: 20061922142192-s2.0-3334446168716448896
20. Manisty CH,Hughes AD. Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation indexBritish Journal of Clinical PharmacologyYear: 2013751799222625662
21. Fagard RH,Celis H,Thijs L,Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studiesHypertensionYear: 2009545108410912-s2.0-7044973079219770405
22. Kampus P,Serg M,Kals J,et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thicknessHypertensionYear: 2011576112211282-s2.0-7995634374921536983
23. Gapon LI,Prilepova AA,Tsygol’nik MD. Effect of nebivolol on parameters of cerebral haemodynanics and 24-hour blood pressure profile in patients with arterial hypertensionKardiologiyaYear: 2005451018222-s2.0-3364545277716234763
24. Fountoulaki K,Dimopoulos V,Giannakoulis J,Zintzaras E,Triposkiadis F. Left ventricular mass and mechanics in mild-to-moderate hypertension: effect of nebivolol versus telmisartanAmerican Journal of HypertensionYear: 2005182, part 11711772-s2.0-1474430289315752943
25. Shahin Y,Khan JA,Samuel N,Chetter I. Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trialsAtherosclerosisYear: 201121617162-s2.0-7995554683021411098
26. Bank AJ,Kelly AS,Thelen AM,Kaiser DR,Gonzalez-Campoy JM. Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitusAmerican Journal of HypertensionYear: 20072077777832-s2.0-3425063858717586413
27. Pasini AF,Garbin U,Stranieri C,et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patientsAmerican Journal of HypertensionYear: 20082111125112572-s2.0-5424910716018772860
28. Messerli FH,Bangalore S,Julius S. Risk/benefit assessment of β-blockers and diuretics precludes their use for first-line therapy in hypertensionCirculationYear: 200811720270627152-s2.0-4764908569418490538
29. Bakris GL,Fonseca V,Katholi RE,et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trialThe Journal of the American Medical AssociationYear: 200429218222722362-s2.0-7744237066
30. Messerli FH,Bell DSH,Fonseca V,et al. Body weight changes with β-blocker use: results from GEMINIThe American Journal of MedicineYear: 200712076106152-s2.0-3425090037917602935
31. Kohro T,Hayashi D,Yamazaki T,Nagai R. Beta-blocker prescription among Japanese cardiologists and its effect on various outcomesCirculation JournalYear: 20107459629692-s2.0-7795171552020234099
32. Wikstrand J,Warnold I,Tuomilehto J,et al. Metoprolol versus thiazide diuretics in hypertension: morbidity results from the MAPHY studyHypertensionYear: 19911745795882-s2.0-00258762372013485
33. Turnbull F,Neal B,Ninomiya T,et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger people: meta-analysis of randomised trialsBritish Medical JournalYear: 20083367653112111232-s2.0-4434910115218480116
34. Luijendijk HJ,van den Berg JF,Hofman A,Tiemeier H,Stricker BHC. β-blockers and the risk of incident depression in the elderlyJournal of Clinical PsychopharmacologyYear: 201131145502-s2.0-7865128574421192142
35. Bangalore S,Sawhney S,Messerli FH. Relation of beta-blocker—induced heart rate lowering and cardioprotection in hypertensionJournal of the American College of CardiologyYear: 20085218148214892-s2.0-5394908652819017516
36. Jouven X,Empana J-P,Schwartz PJ,Desnos M,Courbon D,Ducimetière P. Heart-rate profile during exercise as a predictor of sudden deathThe New England Journal of MedicineYear: 200535219195119582-s2.0-1834436749615888695
37. Tomiyama H,Hashimoto H,Tanaka H,et al. Synergistic relationship between changes in the pulse wave velocity and changes in the heart rate in middle-aged Japanese adults: a prospective studyJournal of HypertensionYear: 20102846876942-s2.0-7865077439720051904
38. KDIGO Blood Pressure Work GroupKDIGO clinical practice guideline for the management of blood pressure in chronic kidney diseaseKidney International SupplementsYear: 201225, supplement337414
39. Verbeke F,Lindley E,Van Bortel L,et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease: improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Non-dialysis-dependent Chronic Kidney Disease: an endorsement with some caveats for real-life applicationNephrology Dialysis TransplantationYear: 2013
40. Petras D,Koutroutsos K,Kordalis A,Tsioufis C,Stefanadis C. The role of sympathetic nervous system in the progression of chronic kidney disease in the era of catheter based sympathetic renal denervationCurrent Clinical PharmacologyYear: 20138319720523173962
41. Zoccali C,Mallamaci F,Parlongo S,et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal diseaseCirculationYear: 200210511135413592-s2.0-003713363311901048
42. Ptinopoulou AG,Pikilidou MI,Lasaridis AN. The effect of antihypertensive drugs on chronic kidney disease: a comprehensive reviewHypertension ResearchYear: 20133629110123051659
43. Wright RS,Reeder GS,Herzog CA,et al. Acute myocardial infarction and renal dysfunction: a high-risk combinationAnnals of Internal MedicineYear: 200213775635702-s2.0-003678882812353943
44. Abbott KC,Trespalacios FC,Agodoa LY,Taylor AJ,Bakris GL. β-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortalityArchives of Internal MedicineYear: 200416422246524712-s2.0-1034426647415596637
45. Kidney Disease Outcomes Quality Initiative (K/DOQI)K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney diseaseAmerican Journal of Kidney DiseasesYear: 200443supplement 15S1S29015114537
46. Bakris GL,Copley JB,Vicknair N,Sadler R,Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathyKidney InternationalYear: 1996505164116502-s2.0-00299612078914031
47. Holman R,Turner R,Stratton I,et al. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39British Medical JournalYear: 199831771607137202-s2.0-00325116019732338
48. Wright JT Jr.,Bakris G,Greene T,et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trialThe Journal of the American Medical AssociationYear: 200228819242124312-s2.0-0037145856
49. Fassbinder W,Quarder O,Waltz A. Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicentre randomised studyInternational Journal of Clinical PracticeYear: 19995375195222-s2.0-003274301910692737
50. Bakris GL,Weir MR,Secic M,Campbell B,Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progressionKidney InternationalYear: 2004656199120022-s2.0-244270394215149313
51. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysisSeminars in DialysisYear: 20031621011052-s2.0-004207322312641872
52. Green D,Roberts PR,New DI,Kalra PA. Sudden cardiac death in hemodialysis patients: an in-depth reviewAmerican Journal of Kidney DiseasesYear: 20115769219292-s2.0-7995635214421496983
53. Badve SV,Roberts MA,Hawley CM,et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and meta-analysisJournal of the American College of CardiologyYear: 20115811115211612-s2.0-8005236539021884954
54. Tangri N,Shastri S,Tighiouart H,et al. β-blockers for prevention of sudden cardiac death in patients on hemodialysis: a propensity score analysis of the HEMO studyAmerican Journal of Kidney DiseasesYear: 20115869399452-s2.0-8175516149621872979
55. Ritz E,Rump LC. Do β-blockers combined with RAS inhibitors make sense after all to protect against renal injury?Current Hypertension ReportsYear: 2007954094142-s2.0-3684901145818177589

Article Categories:
  • Review Article

Previous Document:  Clinical significance of optic disc progression by topographic change analysis maps in glaucoma: an ...
Next Document:  The impact of mood and anxiety disorders on incident hypertension at one year.